An Alternative Approach to Drug Treatment in Psychiatry
This article explores an alternative understanding of how psychiatric drugs work that is referred to as the “drug-centred” model of drug action. Unlike the standard “disease-centred” model, which suggests that psychiatric drugs work by correcting an underlying brain abnormality, the drug-centred model emphasises how psychiatric drugs affect mental states and behaviour by modifying normal brain processes. The alterations produced are superimposed on the emotional and behavioural problems that constitute the symptoms of mental disorders. The chapter examines research into drug action to show the dearth of support for the disease-centred model. It then explores the clinical implications of adopting a drug-centred model of drug action. This requires a detailed understanding of the mental and physical alterations produced by individual drugs and an exploration of how those alterations might interact with particular sets of symptoms and problems. Drug-centred approaches to the drug treatment of psychosis and depression are presented as examples. It is concluded that any benefits due to being in an altered state need to be carefully balanced against the damage that may occur with long-term exposure and that we need further research to elucidate all the consequences of using drugs in this way.
KeywordsPsychopharmacology Antipsychotics Antidepressants Models of drug action
- 2.Alexander J, Tharyan P, Adams C, John T, Mol C, Philip J. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v haloperidol plus promethazine. Br J Psychiatry. 2004;185:63–9. Available from: PM:15231557CrossRefGoogle Scholar
- 3.American Psychiatric Association. Lets talk facts about depression. Ref type: pamphlet. Washington, DC; 2005.Google Scholar
- 7.Breggin P. Brain-disabling treatments in psychiatry. 2nd ed. New York: Springer Publishing Company; 2008.Google Scholar
- 9.Casey JF, Lasky JJ, Klett CJ, Hollister LE. Treatment of schizophrenic reactions with phenothiazine derivatives. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine, and phenobarbital. Am J Psychiatr. 1960b;117:97–105. Available from: PM:13808146CrossRefGoogle Scholar
- 11.Dubovsky SL, Davies R, Dubovsky AN. Mood Disorders. In: Hales RE, Yudofsky SC, editors. Textbook of clinical psychiatry. Washington, DC: American Psychiatric Association; 2001.Google Scholar
- 12.Eli Lilly. (2006) Zyprexa website. www.zyprexa.com/bipolar/treating.asp. 7-12-2006. Ref type: electronic citation.
- 22.Moncrieff J. The myth of the chemical cure: a critique of psychiatric drug treatment. Basingstoke: Palgrave Macmillan; 2008.Google Scholar
- 24.Moncrieff J. Antipsychotic maintenance treatment: time to rethink? PLoSMed. 2015;12(8):e1001861. Available from: PM:26241954Google Scholar
- 31.Prien RF, Caffey EM Jr, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry. 1972;26(2):146–53. Available from: PM:4551257CrossRefGoogle Scholar
- 33.Royal College of Psychiatrists. Antidepressants. London: Royal College of Psychiatrists; 2009. Ref type: pamphlet.Google Scholar
- 35.Stahl SM. Stahl’s essential psychopharmacology. 4th ed. Cambridge: Cambridge University Press; 2013.Google Scholar